EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY-NC 4.0

PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis

Jun Li, Chun Liao, Zhaohui Liu, Hu Xiong, Jing Cai, Tiande Liu iD

Technology in Cancer Research & Treatment · 2024

DOI: 10.1177/15330338241305700 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Technology in Cancer Research & Treatment, 2024. Verfasst von Jun Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Angiogenesis Inhibitors, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Natural Science Foundation General Project of Jiangxi, Jiangxi Provincial Health Department Project, Training Program for Academic and technical leaders in major disciplines in Jiangxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For advanced hepatocellular carcinoma (HCC), sorafenib remains the established therapy. PD-1/PD-L1 inhibitors plus antiangiogenic drugs (PIAD) as a new therapeutic approach for advanced HCC is still a subject of clinical debate regarding whether they offer improved treatment outcomes. This study was conducted to compare the two treatments in terms of antitumor efficacy and safety.

Methods

Randomized controlled trials (RCTs) comparing PIAD and sorafenib for advanced HCC were retrieved from six databases. Survival (overall survival [OS] and progression-free survival [PFS]) were the main outcomes measured. Secondary endpoints included responses, adverse events (AEs), and effects on quality of life.

Results

Seven studies based on four RCTs (CARES-310, COSMIC-312, IMbrave150, and ORIENT-32) were included. The PIAD group exhibited better OS (hazard ratio [HR]: 0.69, 95% confidence interval [CI]: [0.53, 0.89], P = 0.005), and PFS (HR: 0.60, 95% CI: [0.53, 0.67], P < 0.00001). The survival advantages of OS and PFS were confirmed in almost all subgroups. The PIAD group exhibited higher OS rates at 6–18 months and PFS rates at 6–12 months. Additionally, the objective response rate, disease control rate, complete response, and partial response were higher in PIAD group. The PIAD group had a delayed decline in quality of life, physical functioning, and role functioning. However, the PIAD group experienced more grades 3–5 and serious AEs, along with treatment discontinuation, dose reduction, and dose interruption.

Conclusions

PIAD appears to be better than sorafenib for advanced HCC with better survival and responses. However, its higher rate of AEs requires cautious attention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Angiogenesis InhibitorsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularImmune Checkpoint InhibitorsLiver NeoplasmsSorafenibHumansB7-H1 AntigenClinical Trials, Phase III as TopicNeoplasm StagingProgrammed Cell Death 1 ReceptorQuality of LifeRandomized Controlled Trials as TopicTreatment Outcome

Stichwörter der Autor:innen

PD-1/PD-L1 inhibitorsantiangiogenic drugshepatocellular carcinomameta-analysissorafenib

Substanzen

Angiogenesis InhibitorsB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorSorafenib

Autor:innen und Institutionen

  • Department of General Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.
  • Department of Oncology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China.

ORCID-Profile: Tiande Liu

Förderung

  • Natural Science Foundation General Project of Jiangxi
  • Jiangxi Provincial Health Department Project
  • Training Program for Academic and technical leaders in major disciplines in Jiangxi Province

Zitieren

APA

Li, J., Liao, C., Liu, Z., Xiong, H., Cai, J., & Liu, T. (2024). PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis. Technology in Cancer Research & Treatment. https://doi.org/10.1177/15330338241305700

Vancouver

Li J, Liao C, Liu Z, Xiong H, Cai J, Liu T. PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis. Technology in Cancer Research & Treatment. 2024. doi:10.1177/15330338241305700

BibTeX
@article{Li2024,
  author = {Li, Jun and Liao, Chun and Liu, Zhaohui and Xiong, Hu and Cai, Jing and Liu, Tiande},
  title = {PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis},
  journal = {Technology in Cancer Research & Treatment},
  year = {2024},
  doi = {10.1177/15330338241305700}
}
Kostenlos starten →